Latest News
Web Date: December 12, 2017

CRISPR gene editing is coming to the clinic

Hematology meeting offers glimpse of clinical trials that will use CRISPR to treat sickle cell disease and beta-thalassemia beginning in 2018
Department: Business
Keywords: Biotechnology, CRISPR, CRISPR Therapeutics, sickle cell disease, beta thalassemia, gene therapy, hemoglobin

The gene editing technology CRISPR is one step closer to treating genetic diseases in humans. Last week, Crispr Therapeutics filed an application with European regulatory authorities to begin clinical trials for its CRISPR therapy CTX001 in a genetic blood condition called beta-thalassemia. The biotech firm expects to begin the trial—the first industry-sponsored study of a CRISPR drug—next year.

“It is a momentous occasion for both our company and the field,” says Samarth Kulkarni, CEO of . . .

To view the rest of this content, please log in with your ACS ID.



 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society